KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares Outstanding
Ratios

Biogen (BIIB) Accumulated Depreciation & Amortization (2016 - 2026)

Biogen has reported Accumulated Depreciation & Amortization over the past 18 years, most recently at $204.4 million for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization rose 11.57% year-over-year to $204.4 million; the TTM value through Mar 2026 reached $204.4 million, up 11.57%, while the annual FY2025 figure was $779.9 million, 15.85% up from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2026 was $204.4 million at Biogen, down from $779.9 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $779.9 million in Q4 2025 and troughed at $112.3 million in Q1 2023.
  • A 5-year average of $368.9 million and a median of $354.7 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 39.47% in 2022 and later fell 21.52% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $518.4 million in 2022, then dropped by 4.55% to $494.8 million in 2023, then skyrocketed by 36.05% to $673.2 million in 2024, then increased by 15.85% to $779.9 million in 2025, then crashed by 73.79% to $204.4 million in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for BIIB at $204.4 million in Q1 2026, $779.9 million in Q4 2025, and $579.7 million in Q3 2025.